Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis

Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration

(2023) Gerry Shaw et al.   Brain Communications

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

(2022) Arie R. Gafson et al.   JAMA Network Open

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

(2022) Pascal Benkert et al.   LANCET NEUROLOGY

Blood Neurofilament Light in Progressive Multiple Sclerosis

(2022) David Leppert et al.   NEUROLOGY

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

(2022) Alessandro Cagol et al.   JAMA Neurology

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials

(2022) Tjalf Ziemssen et al.   Frontiers in Immunology

Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis

(2022) Ahmed Abdelhak et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

(2022) Carmen Tur et al.   JAMA Neurology

Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis

(2021) Claire Bridel et al.   NEUROLOGY

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study

(2021) Timo Uphaus et al.   EBioMedicine

Serum neurofilament light levels in normal aging and their association with morphologic brain changes

(2020) Michael Khalil et al.   Nature Communications

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

(2020) Ludwig Kappos et al.   JAMA Neurology

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

(2019) Ester Cantó et al.   JAMA Neurology

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Unknown

(2016)   ANNALS OF NEUROLOGY

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

(2016) Giulio Disanto et al.   PLoS One